Nyxoah SA Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on August 11, 2025, covers the month of August 2025 and provides preliminary, unaudited financial results for the second quarter ended June 30, 2025. Nyxoah SA is a medical device company focused on the Genio® system for the treatment of Obstructive Sleep Apnea (OSA). The filing highlights a major regulatory milestone with U.S. FDA approval and updates on clinical trials and R&D restructuring.
Key Financial Metrics
| Metric | Q2 2025 (Preliminary) | Q2 2024 (Prior Period) | Change |
|---|---|---|---|
| Revenue | €1.3 million | Not explicitly stated | +73% |
| Operating Expenses | €20.7 million | Not explicitly stated | +50% |
| Cash, Cash Equivalents & Financial Assets | €43.0 million (as of June 30, 2025) | N/A | N/A |
| Net Profit/Loss | Not provided | Not provided | N/A |
| Debt | Not provided | Not provided | N/A |
Note: Financial figures are preliminary estimates and subject to change upon the filing of the complete Second Quarter 2025 Report.
Material Changes and Business Updates
- FDA Approval: On August 8, 2025, the U.S. FDA approved the Genio® system for a subset of adult patients with moderate to severe OSA (AHI ≥ 15 and ≤ 65).
- Revenue Growth: Q2 2025 revenue is anticipated to increase by 73% year-over-year, driven by commercial expansion.
- Expense Increase: Operating expenses rose 50% year-over-year, reflecting increased commercialization and R&D activities.
- Clinical Trial Update: The Company expects to close patient enrollment in the ACCCESS clinical trial prior to reaching the full 106-patient target. The study will proceed with currently enrolled patients, assessing endpoints at 12 months post-implant with a five-year follow-up.
- R&D Restructuring: Nyxoah is reorganizing its global R&D function, transitioning all ongoing activities from Israel to the United States and Belgium.
Guidance, Outlook, and Risks
Outlook and Strategy: The Company is preparing for a U.S. commercial launch, intending to cover approximately 30% of the existing U.S. Hypoglossal Nerve Stimulation (HGNS) market with 25 territory managers. Success depends on market acceptance, physician adoption, and reimbursement levels.
Material Risks:
- Intellectual Property Litigation: On May 30, 2025, Inspire Medical Systems, Inc. filed a lawsuit alleging the Genio system infringes certain patents. The outcome is uncertain and could result in significant costs, injunctions, or royalty payments.
- Regulatory Uncertainty: While FDA approval was granted for a specific subset of patients, future regulatory actions, policy changes, or staffing reductions at the FDA could impact review timelines and market access.
- Geopolitical and Economic Factors: Risks include the ongoing conflict in Israel (where R&D was previously located), the war in Ukraine, global inflation, and potential U.S. tariff increases on imports.
- Commercialization Challenges: The Company has limited experience in U.S. sales and marketing. Failure to recruit, train, and retain a qualified sales force could delay revenue growth.
Investor Verification Checklist
- Verify the final audited Q2 2025 financial results when the full report is filed to confirm the preliminary revenue and expense estimates.
- Monitor the status of the patent infringement lawsuit filed by Inspire Medical Systems, Inc., including any court rulings or settlement discussions.
- Track the progress of the U.S. commercial launch, specifically the hiring and training of the 25 territory managers and initial sales performance.
- Review the final data from the ACCCESS clinical trial once the 12-month post-implant assessment is complete.
- Assess the impact of the R&D transition from Israel to the U.S. and Belgium on operational costs and timelines.